Latest United States News

Harvest Technology Group has transitioned from assessing to actively executing its international defence market strategy by engaging a US national security advisory firm and appointing Dr Oleksandra Molloy as Defence Strategic Advisor for Europe.

Toro Energy’s takeover by IsoEnergy has officially become effective following Federal Court approval, setting key dates for share trading suspension and scheme implementation.

Amara Minerals secured a $2.2 million placement at a 25% premium, with Nova Minerals increasing its strategic investment by $500,000. Meanwhile, Nova Minerals completed its redomiciliation to the US, listing on NYSE American and delisting from ASX.

Cobalt Blue Holdings and Glomar Minerals have shortlisted four US sites and begun testwork for Project Infinity, aiming to build the first commercial polymetallic nodule refinery in the United States.

OD6 Metals reveals multi-element assay results from its Quinn Fluorspar Project showing exceptionally low impurities and high fluorspar grades, supporting potential direct shipping Metspar and upgraded AcidSpar products.

Delegat Group has raised its full-year Operating Net Profit after Tax forecast to $60-62 million, up from $50-55 million, driven by stronger global sales, lower US tariffs, and favourable FX.

PMET Resources has endorsed NRW Holdings’ ALi® atmospheric leach process for producing battery-grade lithium carbonate, highlighting its economic and environmental advantages. NRW is advancing commercialisation with ongoing testing and development plans.

Electro Optic Systems (ASX:EOS) reports sustained demand driven by global conflicts, launches MARSS business in Europe, and updates 2026 revenue outlook with base business guidance of $240m to $270m.

GCM Corporation expands its VHD heat sink portfolio to 44 products and moves into liquid cooling OEM markets for AI servers, securing global distribution via DigiKey.

Nova Minerals' US holding company shares and warrants are slated to begin trading on NYSE American on 17 June 2026, with ASX trading of CHESS Depositary Interests following on 18 June, marking a key step in the company’s US redomiciliation.

Neurizon Therapeutics has dosed over 50% of participants in the HEALEY ALS Platform Trial's Regimen I, exceeding recruitment expectations after expanding the cohort from 160 to 240 patients. The accelerated pace puts the company on track for last patient dosing in Q2 2027 and topline results by early Q3 2027.

Amaero Ltd’s Federal Court-approved re-domiciliation schemes take effect on 11 June 2026, halting ASX trading of existing shares and paving the way for new US HoldCo CDIs to list.